Raras
Buscar doenças, sintomas, genes...
Beriliose crônica
ORPHA:133CID-10 · J63.2CID-11 · CA60.6DOENÇA RARA

A Doença Crônica do Berílio (DCB) é uma doença inflamatória dos pulmões caracterizada pela formação de pequenos nódulos (granulomas) e que afeta o tecido de suporte pulmonar. Ela surge em pessoas que desenvolvem sensibilidade ao berílio (SBe), uma reação específica do sistema de defesa do corpo à exposição a essa substância no ambiente ou no trabalho. A sensibilidade ao berílio (SBe) costuma surgir antes da doença pulmonar, cujos sintomas podem incluir tosse seca persistente, cansaço, perda de peso, dor no peito e falta de ar que piora com o tempo.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A Doença Crônica do Berílio (DCB) é uma doença inflamatória dos pulmões caracterizada pela formação de pequenos nódulos (granulomas) e que afeta o tecido de suporte pulmonar. Ela surge em pessoas que desenvolvem sensibilidade ao berílio (SBe), uma reação específica do sistema de defesa do corpo à exposição a essa substância no ambiente ou no trabalho. A sensibilidade ao berílio (SBe) costuma surgir antes da doença pulmonar, cujos sintomas podem incluir tosse seca persistente, cansaço, perda de peso, dor no peito e falta de ar que piora com o tempo.

Publicações científicas
437 artigos
Último publicado: 2026 Apr 13

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Adult
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: J63.2
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫁
Pulmão
11 sintomas
🛡️
Imunológico
1 sintomas
📏
Crescimento
1 sintomas
🩸
Sangue
1 sintomas
🧬
Pele e cabelo
1 sintomas

+ 4 sintomas em outras categorias

Características mais comuns

90%prev.
Fisiologia anormal do sistema respiratório
Muito frequente (99-80%)
90%prev.
Pneumonite por hipersensibilidade
Muito frequente (99-80%)
90%prev.
Hipersensibilidade imunológica
Muito frequente (99-80%)
55%prev.
Morfologia traqueobrônquica anormal
Frequente (79-30%)
55%prev.
Perda de peso
Frequente (79-30%)
55%prev.
Padrão reticulonodular na TC de alta resolução pulmonar
Frequente (79-30%)
19sintomas
Muito frequente (3)
Frequente (13)
Ocasional (2)
Muito raro (1)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 19 características clínicas mais associadas, ordenadas por frequência.

Fisiologia anormal do sistema respiratórioAbnormal respiratory system physiology
Muito frequente (99-80%)90%
Pneumonite por hipersensibilidadeHypersensitivity pneumonitis
Muito frequente (99-80%)90%
Hipersensibilidade imunológicaImmunologic hypersensitivity
Muito frequente (99-80%)90%
Morfologia traqueobrônquica anormalAbnormal tracheobronchial morphology
Frequente (79-30%)55%
Perda de pesoWeight loss
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico437PubMed
Últimos 10 anos83publicações
Pico202011 papers
Linha do tempo
2026Hoje · 2026🧪 2005Primeiro ensaio clínico📈 2020Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Not applicable.

HLA-DPB1HLA class II histocompatibility antigen, DP beta 1 chainMajor susceptibility factor inTolerante
FUNÇÃO

Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC

LOCALIZAÇÃO

Cell membraneEndoplasmic reticulum membraneGolgi apparatus, trans-Golgi network membraneEndosome membraneLysosome membrane

VIAS BIOLÓGICAS (7)
Generation of second messenger moleculesTranslocation of ZAP-70 to Immunological synapsePhosphorylation of CD3 and TCR zeta chainsCo-inhibition by PD-1Downstream TCR signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
298.6 TPM
Baço
261.2 TPM
Pulmão
218.9 TPM
Nervo tibial
117.2 TPM
Tecido adiposo
103.4 TPM
OUTRAS DOENÇAS (2)
granulomatosis with polyangiitischronic beryllium disease
HGNC:4940UniProt:P04440

Variantes genéticas (ClinVar)

8 variantes patogênicas registradas no ClinVar.

🧬 HLA-DPB1: NM_002121.6(HLA-DPB1):c.364+267A>G ()
🧬 HLA-DPB1: NM_002121.6(HLA-DPB1):c.364+132G>T ()
🧬 HLA-DPB1: NM_001242525.2(HLA-DPA1):c.-24G>C ()
🧬 HLA-DPB1: GRCh37/hg19 6p21.33-21.31(chr6:31036397-34088832)x3 ()
🧬 HLA-DPB1: GRCh37/hg19 6p22.1-q14.1(chr6:29455465-81447367) ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 22
·Pré-clínico3
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 5 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Beriliose crônica

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

6 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
86 papers (10 anos)
#1

New aspects of chronic beryllium disease.

Current opinion in allergy and clinical immunology2026 Apr 01

Chronic beryllium disease (CBD) is a granulomatous lung disorder resulting from a cell-mediated immune response to beryllium exposure. Despite exposure regulations, new cases continue to emerge across both traditional and nontraditional occupational settings. In this review, we underscore ongoing diagnostic and preventive challenges, and strategies for screening and treatment of beryllium exposed patients. Recent updates to exposure standards and medical surveillance have broadened recognition of at-risk populations, including military personnel and construction workers. Advances in understanding the immunopathogenesis of CBD - particularly the central role of beryllium-specific CD4 + T cells and the strong genetic association with HLA-DPB1 alleles containing glutamic acid at position 69 (Glu69) - have provided critical insight into disease susceptibility and progression. However, gaps persist in access to testing, biomarker development, and understanding the natural history of sensitization and disease progression. Treatment remains centered on corticosteroids, with emerging but limited evidence for immunomodulatory and biologic therapies. Future directions include development of improved diagnostic biomarkers, refinement of screening protocols, and multicenter trials assessing steroid-sparing regimens. Coordinated translational and occupational research is essential to address persistent diagnostic uncertainty, reduce morbidity, and guide evidence-based management for affected individuals.

#2

Interstitial Lung Diseases Presenting as Small Nodules: Imaging Phenotypes.

Seminars in roentgenology2026 Jan

Interstitial lung disease (ILD) encompasses a diverse range of conditions that lead to inflammation and/or scarring of the lung interstitium, often affecting airspaces and resulting in a progressive decline in lung function. High-Resolution Computed Tomography (HRCT) is a crucial diagnostic tool for ILDs, and their characterization based on imaging. This article specifically focuses on ILD presentations characterized by small lung nodules on HRCT, defined as those measuring less than 10 mm. Small nodules on HRCT are analyzed based on size, distribution, borders, attenuation, associated findings, and temporal evolution to narrow diagnostic considerations. A key factor is the distribution pattern, which is placement within the secondary pulmonary lobule and axial interstitium. Based on their distribution pattern relative to the anatomical core of the lobule, small nodules are classified into 3 specific imaging phenotypes: perilymphatic, centrilobular, and random. Perilymphatic nodular phenotypes typically involve disease processes affecting the pulmonary lymphatics along the interlobular septa, pleura, fissures, and/or bronchovascular bundles. Common conditions include Sarcoidosis, Occupational lung diseases such as coal worker pneumoconiosis (CWP) and silicosis, Chronic beryllium disease, Granulomatous and Lymphocytic interstitial lung disease (GL-ILD), Pulmonary septal amyloidosis, Pulmonary alveolar microlithiasis, Diffuse Pulmonary Ossification. Centrilobular nodular phenotypes are centered on the core structures of the secondary pulmonary lobule, including bronchioles, pulmonary arterioles, and central lymphatic vessels. They can be nonbranching (solid or ground-glass attenuation) or branching, often appearing as a "tree-in-bud" morphology. Nonbranching centrilobular nodules are seen in conditions such as Nonfibrotic hypersensitivity pneumonitis (HP), Respiratory bronchiolitis (RB), Follicular bronchiolitis (FB), Lymphocytic interstitial pneumonitis (LIP), Metastatic pulmonary calcification (MPC), Pulmonary hemosiderosis, and Pulmonary Langerhans cell histiocytosis (LCH). Branching centrilobular nodules ("tree-in-bud") are typically not associated with ILDs and often indicate Infectious bronchiolitis, Aspiration and other disorders. Random pulmonary nodular phenotypes refer to nodules without a consistent relationship to the secondary lobule or other lung structures. While profuse perilymphatic nodules (e.g., in sarcoidosis and occupational lung diseases) can appear randomly distributed, true random patterns are characteristic of hematogenous infections or miliary metastases.

#3

Refining Beryllium Lymphocyte Proliferation Testing for Equitable Chronic Beryllium Disease vs Sarcoidosis Differentiation.

Chest2026 Feb
#4

Additional diagnostic potential of transbronchial lung cryobiopsy in bronchoscopic assessment of sarcoidosis and chronic beryllium disease: a retrospective analysis of 321 patients.

BMJ open respiratory research2025 Dec 17

Non-necrotising granulomas are the histological hallmark of sarcoidosis and chronic beryllium disease (CBD). Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), transbronchial lung forceps biopsy (TBLB) and endobronchial biopsy (EBB) are often used as standard methods for obtaining suitable tissue. Transbronchial lung cryobiopsy (TBLC) is a novel biopsy technique well studied in different fibrosing lung diseases; however, data on its use in sarcoidosis are scarce. This study aimed to assess whether TBLC provides additional diagnostic value compared with standard diagnostic methods in detecting non-necrotising granulomas. We retrospectively analysed 321 patients diagnosed with sarcoidosis or CBD between 2010 and 2020 in a single tertiary care centre. Patients who underwent intrathoracic biopsy were analysed to assess the diagnostic yield, factors influencing diagnostic success, as well as complications related to each technique. Intrathoracic biopsy procedures were performed on 264 patients (EBUS-TBNA n=215, EBB n=61, TBLB n=120 and TBLC n=66). The diagnostic yields for single methods ranged from 56.3% (EBB) to 63.6% (TBLC) (p=0.7643). Combination of EBUS-TBNA with TBLC increased the diagnostic yield to 91.7%. Notably, TBLC provided a superior diagnostic yield compared with TBB in cases without radiologically detected parenchymal involvement. Complication rates were numerically higher following TBLC compared with TBLB (16.7% vs 9.2%, p=0.1561). The addition of TBLC significantly enhances the diagnostic yield in the workup of sarcoidosis and CBD, particularly in cases without radiologically detected parenchymal involvement. This underscores the added value of TBLC in improving diagnostic accuracy in challenging clinical scenarios.

#5

Genome-wide association study and HLA genotyping for beryllium disease susceptibility in a European descent population.

Gene2025 Nov 05

Workplace exposure to beryllium can result in beryllium sensitization (BeS), a cell-mediated immune response that can progress to chronic beryllium disease (CBD), a granulomatous lung disease. DPB1-E69 is highly associated with CBD and BeS, although DRB1-E71 may also be a risk factor in the absence of DPB1-E69. This study 1) identified novel genetic variants associated with CBD/BeS using a genome-wide association study (GWAS) approach and 2) clarified the role of DRB1-E71 in conjunction with DPB1-E69. We performed GWAS and HLA analysis on 1626 subjects with BeS, CBD and beryllium exposure without disease. We found that rs1042140, the first base of the codon that encodes E69, was associated with CBD and BeS. We also found two single nucleotide polymorphisms (SNPs), rs56011217 and rs72636334, near SRIP1 on chromosome 4 associated with CBD and BeS independent of rs1042140. HLA alleles DRB1*04:04 (non E71) and DQB1*06:04 were significantly associated with CBD and BeS independent of rs1042140. We found both DPB1-E69 and DRB1-E71 carriers have a higher risk of CBD or BeS both independently and jointly, with DPB1-E69 status having higher impact than DRB1-E71 status. DRB1-E71 also increases the risk in subjects without DPB1-E69. Our study also implies that beyond HLA, SRIP1 should be investigated in chronic beryllium disease pathogenesis.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC188 artigos no totalmostrando 83

2026

Refining Beryllium Lymphocyte Proliferation Testing for Equitable Chronic Beryllium Disease vs Sarcoidosis Differentiation.

Chest
2026

New aspects of chronic beryllium disease.

Current opinion in allergy and clinical immunology
2026

Interstitial Lung Diseases Presenting as Small Nodules: Imaging Phenotypes.

Seminars in roentgenology
2025

Additional diagnostic potential of transbronchial lung cryobiopsy in bronchoscopic assessment of sarcoidosis and chronic beryllium disease: a retrospective analysis of 321 patients.

BMJ open respiratory research
2025

Genome-wide association study and HLA genotyping for beryllium disease susceptibility in a European descent population.

Gene
2025

Beryllium Lymphocyte Proliferation Test: Differential Diagnosis of Sarcoidosis and Chronic Beryllium Disease.

Chest
2025

Leukemia Inhibitory Factor via JAK-STAT Signaling Drives Beryllium Sulfate-Induced Epithelial-Mesenchymal Transition in 16HBE Cells.

Journal of applied toxicology : JAT
2025

Interleukin-1 signaling and CD4+ T cells control B cell recruitment to the lungs in chronic beryllium disease.

Frontiers in immunology
2025

Overview of multi-omics approaches for pulmonary sarcoidosis.

EC pulmonology and respiratory medicine
2025

Sarcoidosis in Beryllium Exposed Workers: A Case-Case Study.

American journal of industrial medicine
2024

Multisystemic Beryllium Disease: An Exceptional Case Revealed by a Urinary Tract Granulomatosis.

International journal of molecular sciences
2024

Scoping review of exposure questionnaires and surveys in interstitial lung disease.

BMJ open respiratory research
2024

Hsa_circ_0004214 involved in the epithelial-mesenchymal transition induced by beryllium sulfate through modulating JAK-STAT signaling pathway.

Toxicology research
2024

In Response to: Re: TenHarmsel et al., Mortality Among Individuals Diagnosed With Chronic Beryllium Disease and Beryllium Sensitization.

Journal of occupational and environmental medicine
2024

Re: TenHarmsel et al., Mortality Among Individuals Diagnosed With Chronic Beryllium Disease and Beryllium Sensitization.

Journal of occupational and environmental medicine
2024

Recent progress in beryllium organometallic chemistry.

Chemical communications (Cambridge, England)
2024

Sarcoidosis in the Military May Be Chronic Beryllium Disease.

Chest
2024

Mortality Among Individuals Diagnosed With Chronic Beryllium Disease and Beryllium Sensitization.

Journal of occupational and environmental medicine
2023

Comparing [3H] thymidine LPT and CFSE assay to assess lymphocyte proliferation in beryllium-exposed sarcoidosis patients.

Heliyon
2023

Occupational interstitial lung diseases.

Journal of internal medicine
2023

Occupational Lung Diseases: Spectrum of Common Imaging Manifestations.

Korean journal of radiology
2023

Differential diagnosis of pulmonary sarcoidosis: a review.

Frontiers in medicine
2023

Pathology and Mineralogy of the Pneumoconioses.

Seminars in respiratory and critical care medicine
2022

Elemental analysis of contemporary dental materials regarding potential beryllium content.

Scientific reports
2022

A comprehensive summary of disease variants implicated in metal allergy.

Journal of toxicology and environmental health. Part B, Critical reviews
2022

Multiomic Signatures of Chronic Beryllium Disease Bronchoalveolar Lavage Cells Relate to T-Cell Function and Innate Immunity.

American journal of respiratory cell and molecular biology
2022

Beryllium disease among construction trade workers at Department of Energy nuclear sites: A follow-up.

American journal of industrial medicine
2022

Protective role of tissue-resident Tregs in a murine model of beryllium-induced disease.

JCI insight
2022

Assessment of dermal absorption of beryllium and copper contained in temple tips of eyeglasses.

Toxicology letters
2022

Innate and Adaptive Immunity in Noninfectious Granulomatous Lung Disease.

Journal of immunology (Baltimore, Md. : 1950)
2022

[Sarcoidosis and berylliosis].

Der Internist
2022

Giant Cell Interstitial Pneumonia In Native, Transplanted And Re-Transplanted Lungs 8 Years Apart Without Known Hard Metal Exposure.

International journal of surgical pathology
2022

HLA-DPB1 E69 genotype and exposure in beryllium sensitisation and disease.

Occupational and environmental medicine
2021

Genomic biomarkers in chronic beryllium disease and sarcoidosis.

Respiratory medicine
2021

The emerging role of inorganic elements as potential antigens in sarcoidosis.

Current opinion in pulmonary medicine
2021

Epigenetics and sarcoidosis.

European respiratory review : an official journal of the European Respiratory Society
2021

Chronic Beryllium Disease Finding Requires Reexamination.

Chest
2021

Involvement of Dendritic Cells and Th17 Cells in Induced Tertiary Lymphoid Structures in a Chronic Beryllium Disease Mouse Model.

Mediators of inflammation
2021

Detection of autoreactive CD4+ T cells by MHC class II multimers in HLA-linked human autoimmune diseases.

The Journal of clinical investigation
2021

Analysis of single nucleotide polymorphisms in chronic beryllium disease.

Respiratory research
2021

Beryllium-specific CD4+ T cells induced by chemokine neoantigens perpetuate inflammation.

The Journal of clinical investigation
2020

Pneumoconiosis with a Sarcoid-Like Reaction Other than Beryllium Exposure: A Case Report and Literature Review.

Medicina (Kaunas, Lithuania)
2020

Health aspects of exposure to emissions from burning coal of high beryllium content: interactions with the immune system.

Central European journal of public health
2021

A Cluster of Beryllium Sensitization Traced to the Presence of Beryllium in Concrete Dust.

Chest
2021

[Management of occupational health for adverse health effects of beryllium and its compounds in workplaces - Recent trends and issues in Japan].

Sangyo eiseigaku zasshi = Journal of occupational health
2020

Chronic Beryllium Disease: Update on a Moving Target.

Chest
2020

Granulomatous lung disease: clinical aspects.

Expert review of respiratory medicine
2020

Beryllium coordination chemistry and its implications on the understanding of metal induced immune responses.

Chemical communications (Cambridge, England)
2020

Age-associated B Cells Appear in Patients with Granulomatous Lung Diseases.

American journal of respiratory and critical care medicine
2020

[Diagnostic difficulties of chronic pulmonary berylliosis in France].

Revue des maladies respiratoires
2020

Adaptive Immunity in Pulmonary Sarcoidosis and Chronic Beryllium Disease.

Frontiers in immunology
2020

A role for TNF-α in alveolar macrophage damage-associated molecular pattern release.

JCI insight
2020

Molecular mechanism of Be2+-ion binding to HLA-DP2: tetrahedral coordination, conformational changes and multi-ion binding.

Physical chemistry chemical physics : PCCP
2020

Lack of an Exposure Response and Interaction With HLA-DPβ1 and DRβ1 Polymorphisms in the Development of Beryllium Toxicity in a High Beryllium Exposure Cohort.

Journal of occupational and environmental medicine
2019

Associations of Metrics of Peak Inhalation Exposure and Skin Exposure Indices With Beryllium Sensitization at a Beryllium Manufacturing Facility.

Annals of work exposures and health
2019

Sarcoidosis in a patient clinically diagnosed with silicosis; is silica associated sarcoidosis a new phenotype?

Respiratory medicine case reports
2018

Interstitial pneumonia in a glassblower: think to chronic beryllium disease!

The Pan African medical journal
2019

New insight in beryllium toxicity excluding exposure to beryllium-containing dust: accumulation patterns, target organs, and elimination.

Archives of toxicology
2019

Interstitial Lung Diseases in Developing Countries.

Annals of global health
2019

Occupational exposure to beryllium in French industries.

Journal of occupational and environmental hygiene
2019

Polymorphism of FCGR3A gene in chronic beryllium disease.

Genes and immunity
2018

TLR9 and IL-1R1 Promote Mobilization of Pulmonary Dendritic Cells during Beryllium Sensitization.

Journal of immunology (Baltimore, Md. : 1950)
2019

DNA Methylation Changes in Lung Immune Cells Are Associated with Granulomatous Lung Disease.

American journal of respiratory cell and molecular biology
2018

Immunologic Effects of Beryllium Exposure.

Annals of the American Thoracic Society
2018

Clinical and laboratory factors contributing to uninterpretable beryllium lymphocyte proliferation tests (BeLPT).

American journal of industrial medicine
2018

Effect of inhaled corticosteroids on lung function in chronic beryllium disease.

Respiratory medicine
2017

Clinical tool for disease phenotyping in granulomatous lung disease.

PloS one
2018

5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects.

Lung
2018

[Differential Diagnosis of Mediastinal and Hilar Lymphadenopathy with Focus on Occupational Diseases].

Pneumologie (Stuttgart, Germany)
2017

High-Affinity Interactions of Beryllium(2+) with Phosphatidylserine Result in a Cross-Linking Effect Reducing Surface Recognition of the Lipid.

Biochemistry
2017

Occupational Exposure to Beryllium. Final rule.

Federal register
2016

Chronic Beryllium Disease: The Search for a Dose-Response.

Journal of occupational and environmental medicine
2016

A mortality study of beryllium workers.

Cancer medicine
2016

Research to Practice Implications of High-Risk Genotypes for Beryllium Sensitization and Disease.

Journal of occupational and environmental medicine
2016

Elemental analysis of occupational granulomatous lung disease by electron probe microanalyzer with wavelength dispersive spectrometer: Two case reports.

Respiratory medicine case reports
2016

Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis.

The European respiratory journal
2016

Identification of metal sensitization in sarcoid-like metal-exposed patients by the MELISA® lymphocyte proliferation test - a pilot study.

Journal of occupational medicine and toxicology (London, England)
2016

CpG promoter methylation status is not a prognostic indicator of gene expression in beryllium challenge.

Journal of immunotoxicology
2016

Metal-specific CD4+ T-cell responses induced by beryllium exposure in HLA-DP2 transgenic mice.

Mucosal immunology
2015

Gene-environment interaction from international cohorts: impact on development and evolution of occupational and environmental lung and airway disease.

Seminars in respiratory and critical care medicine
2015

The beryllium bronchoalveolar lavage lymphocyte proliferation test: indicator of beryllium sensitization, inflammation or both?

Inhalation toxicology
2015

Beryllium increases the CD14(dim)CD16+ subset in the lung of chronic beryllium disease.

PloS one
2015

Beryllium and other metal-induced lung disease.

Current opinion in pulmonary medicine
Ver todos os 188 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Beriliose crônica.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Beriliose crônica

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. New aspects of chronic beryllium disease.
    Current opinion in allergy and clinical immunology· 2026· PMID 41538467mais citado
  2. Interstitial Lung Diseases Presenting as Small Nodules: Imaging Phenotypes.
    Seminars in roentgenology· 2026· PMID 41513509mais citado
  3. Refining Beryllium Lymphocyte Proliferation Testing for Equitable Chronic Beryllium Disease vs Sarcoidosis Differentiation.
    Chest· 2026· PMID 41672666mais citado
  4. Additional diagnostic potential of transbronchial lung cryobiopsy in bronchoscopic assessment of sarcoidosis and chronic beryllium disease: a retrospective analysis of 321 patients.
    BMJ open respiratory research· 2025· PMID 41407395mais citado
  5. Genome-wide association study and HLA genotyping for beryllium disease susceptibility in a European descent population.
    Gene· 2025· PMID 41075949mais citado
  6. Beryllium Sulfate-Induced Cellular Senescence via the IL-6/STAT3 Pathway to Promote Pulmonary Fibrosis.
    J Appl Toxicol· 2026· PMID 41974632recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:133(Orphanet)
  2. MONDO:0015274(MONDO)
  3. GARD:867(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q684810(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Beriliose crônica
Compêndio · Raras BR

Beriliose crônica

ORPHA:133 · MONDO:0015274
Prevalência
Unknown
Herança
Not applicable
CID-10
J63.2 · Beriliose
CID-11
Início
Adult
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0005138
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades